Success Metrics

Clinical Success Rate
69.2%

Based on 9 completed trials

Completion Rate
69%(9/13)
Active Trials
6(19%)
Results Posted
0%(0 trials)
Terminated
4(13%)

Phase Distribution

Ph phase_1
1
3%
Ph phase_4
1
3%
Ph phase_2
3
9%
Ph early_phase_1
1
3%
Ph not_applicable
15
47%
Ph phase_3
1
3%

Phase Distribution

2

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
1(4.5%)
Phase 1Safety & dosage
1(4.5%)
Phase 2Efficacy & side effects
3(13.6%)
Phase 3Large-scale testing
1(4.5%)
Phase 4Post-market surveillance
1(4.5%)
N/ANon-phased studies
15(68.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

64.3%

9 of 14 finished

Non-Completion Rate

35.7%

5 ended early

Currently Active

6

trials recruiting

Total Trials

32

all time

Status Distribution
Active(9)
Completed(9)
Terminated(5)
Other(9)

Detailed Status

unknown9
Completed9
Recruiting5
Terminated4
Not yet recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
6
Success Rate
69.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.5%)
Phase 11 (4.5%)
Phase 23 (13.6%)
Phase 31 (4.5%)
Phase 41 (4.5%)
N/A15 (68.2%)

Trials by Status

recruiting516%
unknown928%
active_not_recruiting13%
not_yet_recruiting39%
terminated413%
withdrawn13%
completed928%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT06103838Phase 2

18F-Fluciclovine PET/CT in Multiple Myeloma

Recruiting
NCT07245849Phase 3

Pericardial Imaging Study

Not Yet Recruiting
NCT03683355

Characterization of RadiOlabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves.

Completed
NCT07430475

Utility of 18F-FDG PET/CT for Suspected Infection in the Inpatient Setting: a Single Centre Retrospective Cohort Study

Completed
NCT07353554Not Applicable

Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma

Not Yet Recruiting
NCT07130344Not Applicable

PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

Not Yet Recruiting
NCT03583528

DOTATOC PET/CT for Imaging NET Patients

Active Not Recruiting
NCT06145399Early Phase 1

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

Withdrawn
NCT06739473Phase 4

Total-body Glucose Utilization in Obesity

Recruiting
NCT06613269Phase 2

68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

Recruiting
NCT02666547Phase 1

68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

Terminated
NCT02666599Not Applicable

Per-operating Use of a Probe for Detection of β+

Terminated
NCT05730608Not Applicable

18F-FDG PET/CT Imaging for Breast Cancer

Recruiting
NCT06224309

Preliminary Assessment of [18F]BL40 in PET/CT Scans

Unknown
NCT05994768

18F-FDG Tomography and Labeled Leukocyte Scintigraphy

Completed
NCT04764721Not Applicable

Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Subjects With a History of Severe COVID-19

Completed
NCT04082988Not Applicable

Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

Terminated
NCT01916005Not Applicable

Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis

Completed
NCT04080271

Role of Positron Emission Tomography/ Computed Tomography (PET/CT) and in Bone Metastases.

Completed
NCT05308888Phase 2

Impact of Local Tissue Inflammation on Intramyocardial Conduction Pathways Post Percutaneous Valve : Evaluation by Positron Emission Tomography on Exploratory Cohort

Unknown

Drug Details

Intervention Type
PROCEDURE
Total Trials
32